Form 4: Cytek Biosciences Director Michael Holder Receives Significant Equity Awards

Cytek Biosciences, Inc. Director Michael Holder was granted 43,973 Restricted Stock Units and 23,809 stock options, aligning his interests with shareholder value.

Summary

• Michael Holder, a Director of Cytek Biosciences, Inc. (CTKB), was granted equity awards on June 18, 2025.
• The awards include 43,973 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the Issuer's common stock.
• Additionally, Mr. Holder received 23,809 Director Stock Options, granting him the right to buy common stock at an exercise price of $3.07 per share.
• Both the RSU Award and the stock options are scheduled to vest 100% on the earlier of June 18, 2026, or the date of the Issuer's 2026 annual meeting of stockholders (provided such meeting is held in June 2026).
• The Director Stock Options have an expiration date of June 18, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a standard, positive corporate governance practice of aligning director incentives with shareholder interests through equity awards, reflecting routine compensation and commitment.

Positives

• The granting of equity awards to Director Michael Holder aligns his financial interests directly with the long-term performance and shareholder value of Cytek Biosciences, Inc.
• This is a standard practice in corporate governance to incentivize board members and foster commitment to the company's success.

Future Outlook

The equity awards granted to Director Michael Holder are subject to future vesting on or after June 18, 2026, aligning his long-term interests with the company's performance and future growth.

Industry Context

Granting equity awards to non-employee directors is a common and widely accepted practice in the biotechnology and life sciences industry. This compensation structure is designed to attract and retain qualified board members while incentivizing them to contribute to the company's long-term success and align their interests with those of shareholders.

Comparison to Industry Standards

• The practice of granting Restricted Stock Units and stock options to directors is standard across publicly traded companies, including those in the biotechnology sector.
• While specific comparable companies or projects are not detailed in this filing, the structure of these equity grants typically aligns with compensation benchmarks for non-employee directors in companies of similar market capitalization and industry, aiming to provide competitive remuneration and strong alignment with shareholder interests.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.

Next Steps

• Vesting of the 43,973 Restricted Stock Units on the earlier of June 18, 2026, or the date of the Issuer's 2026 annual meeting of stockholders (if held in June 2026).
• Vesting of the 23,809 Director Stock Options on the earlier of June 18, 2026, or the date of the Issuer's 2026 annual meeting of stockholders (if held in June 2026).

Key Dates

Keywords

Cytek Biosciences, CTKB, Form 4, SEC filing, insider transaction, director compensation, equity award, restricted stock units, stock options, Michael Holder